Telemonitoring of patient administered score RAPID3 to deliver NICE compliant treatment in rheumatoid arthritis

Telemonitoring of patient administered index RAPID3 to deliver NICE compliant treat-to-target strategy in early rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16316564

Enrollment

Registered

2019-02-12

Start date

2019-07-01

Completion date

Unknown

Last updated

2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis Musculoskeletal Diseases

Interventions

The patients will be randomised in blocks of four to the study or control group to monitor disease activity remotely by using patient administered index RAPID3 or in clinic using clinician administere

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 or above 2. Newly diagnosed RA fulfilling ACR/EULAR 2010 criteria for the diagnosis

Exclusion criteria

Exclusion criteria: 1. Age < 18 years 2. Unable or unwilling to give informed consent 3. Women pregnant, breast feeding or at risk of conceiving 4. Prior treatment with DMARDs 5. Contraindications to DMARD therapy such as recurrent infections, pancytopenia, LFT derangement 6. Mental incapacity to participate in research study, complete RAPID3 and other patient-based study assessments 7. Inability of patient to complete web-based RAPID3 due to the lack of internet facilities or knowledge required to use internet 8. Currently participating or recently participated in another interventional trial

Design outcomes

Primary

Measure	Time frame
Number of patients fulfilling the definition of remission defined as DAS28 <2.6 or low disease activity (DAS28 2,6-3.2) at 12 months of the RA treatment	—

Secondary

Measure	Time frame
1. Time required to achieve remission or low disease activity , measured by DAS28 CRP assessment at 3, 6 and 12 months of the treatment 2. Patient experience of remote monitoring of RA, measured at 12 months of the treatment by using a questionnaire asking for their rating on 0-10 scale of ease of use, simplicity of use, of benefit to them, caused difficulty, satisfaction level with the telemonitoring 3. Feasibility of the study assessed at 6 and 12 months by determining the number of people who have continued to participate in the study with drop out no more than 20% and that the rheumatology team is able to conduct the study without onerous effects on their other commitments 4. Cost effectiveness of telemonitoring of RA to deliver NICE compliant treatment. The cost of individual patient treatment will be calculated at 12 months of the treatment using the trust financial data	—

Measure

Time frame

1. Time required to achieve remission or low disease activity , measured by DAS28 CRP assessment at 3, 6 and 12 months of the treatment 2. Patient experience of remote monitoring of RA, measured at 12 months of the treatment by using a questionnaire asking for their rating on 0-10 scale of ease of use, simplicity of use, of benefit to them, caused difficulty, satisfaction level with the telemonitoring 3. Feasibility of the study assessed at 6 and 12 months by determining the number of people who have continued to participate in the study with drop out no more than 20% and that the rheumatology team is able to conduct the study without onerous effects on their other commitments 4. Cost effectiveness of telemonitoring of RA to deliver NICE compliant treatment. The cost of individual patient treatment will be calculated at 12 months of the treatment using the trust financial data

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026